Search
Search Results
-
CUP-Syndrom – die neue ESMO-Leitlinie
BackgroundThe European Society of Medical Oncology (ESMO) recently published extensively revised guidelines on cancer of unknown primary (CUP). The...
-
ESMO update: upper gastrointestinal cancer
At the European Society for Medical Oncology (ESMO) 2022 annual meeting, several pertinent studies in the field of upper gastrointestinal cancer were...
-
CUP-Syndrom – die neue ESMO-Leitlinie
BackgroundThe European Society of Medical Oncology (ESMO) recently published extensively revised guidelines on cancer of unknown primary (CUP). The...
-
Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation
PurposeOur goal was to identify new anticancer agents approved by the US Food and Drug Administration (FDA) and the European Medical Agency (EMA)...
-
ESMO 2022 personal non-small lung cancer (NSCLC) highlights
In this article, we summarize our personal non-small cell lung cancer (NSCLC) highlights from the ESMO 2022 meeting, covering developments in early-...
-
Selection of phase II/III breast cancer study highlights at the 2022 ESMO annual meeting
The ESMO annual meeting 2022 was held in Paris from September 9th to September 13th 2022. This article aims at presenting highlights of phase II and...
-
Treatment-changing news in urogenital cancer—a brief unstructured narrative review based on findings presented at the ESMO 2023 conference
This article gives an overview through the most promising and practise changing studies presented for urothelial cancer at ESMO 2023 conference.
-
Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS
PurposeThis study aims to estimate changes in the value of oncology drugs over time from initial data of the reimbursement decisions to subsequent...
-
ESMO 2022: spotlight on new emerging treatment options in central nervous system tumors
Nearly 40 abstracts regarding tumors of the central nervous system were presented at the European Society for Medical Oncology (ESMO) Congress in...
-
2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients
Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair the quality of life of patients with various malignancies...
-
Patient and Healthcare Professional Perspectives from ESMO 2022 on Bladder and Kidney Cancer: A Podcast
In this plain language podcast, highlights from the European Society for Medical Oncology (ESMO) Congress are discussed for a second year in a row,...
-
Applicability of ESMO-MCBS and ESCAT for molecular tumor boards
Scoring systems for classifying genomic alterations (GAs) with respect to their potential targeted anticancer therapies (TTs) may be useful for...
-
Aktueller Stand zu „liquid biopsy“ und Diagnostik – Beiträge vom ASCO und ESMO 2022
BackgroundLiquid biopsy is a promising new diagnostic tool that is already used in clinical practice for multiple tumor entities and which also has...
-
Self-Monitoring and Self-Efficacy in Patients with Chronic Kidney Disease During Low-Sodium Diet Self-Management Interventions: Secondary Analysis of the ESMO and SUBLIME Trials
BackgroundPatients with chronic kidney disease are often requested to engage in self-monitoring sodium (i.e. salt) intake, but it is currently...
